XNAS · Healthcare · Biotechnology
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | 0.63 | 0.79 | +25.40% | $149.4M | ✅ Beat | -1.00% | +0.26% | — |
| 2026-02-25 | Q4 2025 | 0.49 | 0.68 | +38.78% | $152.5M | ✅ Beat | -1.45% | -0.68% | -5.87% |
| 2025-11-05 |
| Q3 2025 |
| 0.51 |
| 0.68 |
| +33.33% |
| $148.4M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 0.55 | 0.68 | +23.64% | $146.6M | ✅ Beat | -0.69% | -7.34% | -6.88% |
| 2025-02-26 | Q4 2024 | 0.55 | 0.70 | +27.27% | $141.8M | ✅ Beat | +5.25% | +6.37% | +19.97% |
| 2024-08-07 | Q2 2024 | 0.26 | 0.56 | +115.38% | $122.7M | ✅ Beat | +12.75% | +18.55% | +20.76% |
| 2024-05-08 | Q1 2024 | 0.17 | 0.38 | +123.53% | $98.5M | ✅ Beat | +6.32% | +13.18% | +6.11% |
| 2024-02-28 | Q4 2023 | 0.26 | 0.53 | +103.85% | $110.6M | ✅ Beat | +10.10% | +8.93% | +8.10% |
Showing last 8 quarters.